Innospec Inc. IOSP
- Market cap
- $2.4B
- P/E
- 20.1×
Follow IOSP
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.61 | 54.10 | 53.07 | 56.94 | 56.71 | 81.00 | 83.13 | 91.74 | 103.97 | 70.10 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 73.40 | 74.75 | 83.20 | 107.10 | 107.85 | 107.73 | 115.66 | 125.87 | 133.71 | 117.08 |
High Price
|
|||
| 1,800 | 1,900 | 2,000 | 2,000 | 1,900 | 1,900 | 2,100 | 2,400 | 2,450 | 2,450 |
Employees
|
|||
| 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 883 | 1,307 | 1,477 | 1,513 | 1,193 | 1,483 | 1,964 | 1,949 | 1,845 | 1,778 |
Revenue
|
|||
| 37.62% | 30.86% | 29.45% | 30.81% | 28.72% | 29.32% | 29.88% | 30.33% | 29.42% | 27.69% |
Gross Margin
|
|||
| 103 | 128 | 132 | 150 | 40 | 134 | 185 | 174 | 41 | 138 |
EBT
|
|||
| 11.67% | 9.80% | 8.91% | 9.94% | 3.33% | 9.06% | 9.40% | 8.95% | 2.23% | 7.77% |
EBT Margin
|
|||
| 81 | 62 | 85 | 112 | 29 | 93 | 133 | 139 | 36 | 117 |
Net Income
|
|||
| 38 | 50 | 50 | 48 | 66 | 43 | 40 | 39 | 44 | 44 |
Depreciation
|
|||
| 36.81 | 54.12 | 60.53 | 61.81 | 48.57 | 60.19 | 79.22 | 78.42 | 74.02 | 71.46 |
Revenue/Sh
|
|||
| 3.39 | 2.56 | 3.48 | 4.58 | 1.17 | 3.78 | 5.37 | 5.60 | 1.43 | 4.69 |
Earnings/Sh
|
|||
| 4.40 | 3.42 | 4.30 | 6.60 | 5.94 | 3.78 | 3.30 | 8.34 | 7.40 | 5.56 |
Cash Flow/Sh
|
|||
| (0.69) | (1.33) | (1.23) | (1.27) | (1.21) | (1.47) | (1.70) | (3.10) | (2.48) | (2.99) |
Capex/Sh
|
|||
| 3.71 | 2.09 | 3.07 | 5.33 | 4.73 | 2.31 | 1.60 | 5.24 | 4.92 | 2.57 |
Free CF/Sh
|
|||
| 27.24 | 32.89 | 33.83 | 37.53 | 38.47 | 41.91 | 41.97 | 46.26 | 48.78 | 53.57 |
Book Value/Sh
|
|||
| 24 | 24 | 24 | 24 | 25 | 25 | 25 | 25 | 25 | 25 |
Shares
|
|||
| 20.44 | 27.81 | 17.75 | 22.59 | 77.55 | 23.90 | 19.32 | 21.82 | 76.97 | 16.35 |
PE Ratio
|
|||
| 1.89 | 1.32 | 1.02 | 1.67 | 1.87 | 1.50 | 1.31 | 1.56 | 1.49 | 1.07 |
PS Ratio
|
|||
| 2.55 | 2.16 | 1.83 | 2.76 | 2.36 | 2.16 | 2.47 | 2.64 | 2.26 | 1.43 |
PB Ratio
|
|||
| 2.08 | 1.42 | 1.08 | 1.67 | 1.79 | 1.43 | 1.26 | 1.47 | 1.35 | 0.93 |
EV/Sales
|
|||
| 22.11 | 36.65 | 21.30 | 19.36 | 18.55 | 37.94 | 62.23 | 22.08 | 20.35 | 25.88 |
EV/FCF
|
|||
| 106 | 83 | 105 | 162 | 146 | 93 | 82 | 207 | 185 | 138 |
Op' Cash Flow
|
|||
| (16) | (32) | (30) | (31) | (30) | (36) | (42) | (77) | (62) | (74) |
Capex
|
|||
| 89 | 51 | 75 | 131 | 116 | 57 | 40 | 130 | 123 | 64 |
FCF
|
|||
| 258 | 300 | 367 | 327 | 314 | 392 | 467 | 514 | 585 | 645 |
Working Cap'
|
|||
| 272 | 222 | 209 | 71 | 12 | 36 | 45 | — | — | — |
Total Debt
|
|||
| 170 | 131 | 86 | (5) | (93) | (106) | (102) | (204) | (289) | (292) |
Net Debt
|
|||
| 654 | 794 | 826 | 919 | 945 | 1,033 | 1,040 | 1,150 | 1,216 | 1,333 |
Sh' Equity
|
|||
| 7.36% | 4.77% | 5.90% | 7.63% | 2.00% | 6.27% | 8.38% | 8.40% | 2.07% | 6.54% |
ROA
|
|||
| 7.45% | 8.44% | 9.15% | 10.25% | 2.47% | 8.90% | 12.48% | 10.68% | 12.00% | 7.78% |
ROIC
|
|||
| 12.91% | 8.54% | 10.50% | 12.86% | 3.08% | 9.41% | 12.83% | 12.70% | 3.01% | 9.15% |
ROE
|
|||
Innospec Inc. peers in Specialty Chemicals
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NGVT Ingevity Corporation | $2.5B | 47.4× | Compare |
| FUL H. B. Fuller Company | $2.6B | 14.7× | Compare |
| HWKN Hawkins, Inc. | $2.6B | 33.2× | Compare |
| WDFC WD-40 Company | $2.7B | 30.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CC The Chemours Company | $2.1B | 0.0× | Compare |
| KWR Quaker Houghton | $2.7B | 29.1× | Compare |
| MTX Minerals Technologies Inc. | $2.1B | 0.0× | Compare |
| ASH Ashland Inc. | $3.2B | 60.6× | Compare |
Innospec Inc. (IOSP) key facts
- Innospec Inc. (IOSP) is a Specialty Chemicals company in the Basic Materials sector, listed on Nasdaq.
- Innospec Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 3.65% from fiscal 2024.
- Net income was $116.6 million, or $4.69 per share (basic), a net margin of 6.56%.
- As of September 25, 2026, IOSP traded at $98.72, a market capitalization of $2.4 billion.
- At that price the stock trades at 20.1× trailing-twelve-month earnings and 1.3× sales.
- Innospec Inc. pays an annual dividend of $1.38 per share, a yield of 1.19%, with a payout ratio of 26.6%.
- Return on equity was 9.15% and debt-to-equity 0.00.
Innospec Inc. (IOSP) Latest News
3 Sep
Innospec reported strong quarterly results yet faces notable cash flow issues that warrant attention and could affect its financial outlook. Cash flow problems despite reported strength point to moderate risks for Innospec's ongoing operations and investor view.
12 Aug
Innospec Inc. held its Q2 2026 earnings call, covering financial results, operations and forward outlook. Q2 2026 earnings call supplies performance data and guidance that can shift near-term investor views.
8 Aug
Innospec (IOSP) beat Q2 earnings expectations, prompting analysis on whether the stock remains undervalued. Q2 earnings beat signals moderate positive effects on near-term sentiment without altering core trajectory.
7 Aug
Innospec Inc. (IOSP) posted Q2 earnings above estimates, driven by broad-based growth across operations. Earnings beat signals solid quarterly results but lacks signals of major long-term strategic shifts.
5 Aug
Innospec Inc (IOSP) reported strong growth across all segments in Q2 2026 earnings call, offset by unspecified challenges. Strong growth across segments signals major positive shifts in financial performance and market position.
Innospec Inc. released Q2 earnings call highlights covering financial results, operational updates and forward outlook. Routine quarterly earnings updates typically produce moderate short-term moves in stock price and sentiment without altering long-term trajectory.
4 Aug
Innospec Inc. released financial results for the second quarter of 2026. Quarterly earnings data shapes near-term investor views on performance.
8 Jul
Speculation emerges over suitable buyers for Innospec Inc., a specialty chemicals maker, amid potential acquisition interest that could reshape the company's ownership and operations. Acquisition speculation around Innospec signals major strategic shifts with direct effects on future performance and investor sentiment.
13 May
Innospec Inc. (IOSP) Q1 earnings beat estimates, with sales rising year-over-year fueled by favorable foreign exchange tailwinds. Q1 earnings beat and Y/Y sales growth moderately boost financial performance but depend on temporary FX tailwinds.
11 May
Innospec Inc. reported a 27% EPS beat. Analysts forecast continued positive performance ahead. 27% EPS beat boosts investor sentiment and signals strong financial momentum for future growth.
8 May
Innospec Inc. (IOSP) Q1 2026 earnings call transcript released, detailing quarterly financial performance, operational updates, and management outlook. Q1 2026 earnings transcript reveals financial results and guidance that can significantly sway investor sentiment and stock trajectory.
Innospec Inc. Q1 2026 earnings call summary details quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings call summary discloses financial performance and strategic outlook directly impacting IOSP stock trajectory and investor sentiment.
Innospec Inc. (IOSP) released Q1 earnings call highlights covering financial results, segment performance, operational updates, and outlook. Q1 earnings call highlights moderately influence financial performance and investor sentiment without fundamentally altering long-term trajectory.
7 May
Innospec Inc. (IOSP) reported Q1 earnings per share of $1.70, beating the consensus estimate of $1.63, and revenue of $494.2 million, surpassing expectations of $487.1 million. Exceeding Q1 earnings and revenue estimates positively affects IOSP's short-term financial performance and investor sentiment without fundamentally altering long-term trajectory.
Innospec Inc. (IOSP) reported first quarter 2026 financial results. Quarterly earnings reports affect financial performance assessments and short-term market sentiment.
30 Apr
Analysts expect Innospec Inc. (IOSP) to report declining earnings in upcoming results, with key metrics and factors for investors to monitor. Forecasted earnings decline directly influences IOSP's near-term financial performance and investor sentiment.
24 Apr
Innospec Inc. (IOSP) highlighted as an undiscovered gem in the US market for April 2026. Spotlighting IOSP as an undiscovered gem likely boosts investor sentiment and moderately influences market performance.
20 Apr
Innospec Inc. (IOSP) released its Q4 2024 earnings call transcript, detailing quarterly financial results, operational updates, and management commentary on performance and outlook. Q4 earnings transcripts disclose key financial metrics, guidance, and strategic insights that significantly influence investor sentiment and stock trajectory.
24 Mar
Investors debate betting on Innospec Inc. (IOSP) amid anticipated cash flow inflection despite persistent cost headwinds. Cash flow inflection signals moderate financial improvement for IOSP but cost headwinds limit overall trajectory shift.
17 Mar
Quaker Chemical secures APAC wins in EV fluids, highlighting their pivotal role for market positioning and growth into 2026, with key implications for Innospec Inc. (IOSP). APAC wins in EV fluids by Quaker Chemical signal moderately noticeable shifts in competitive dynamics affecting IOSP's regional strategy and 2026 performance.
Innospec Inc. (IOSP) stock analyzed as potential undervalued investment opportunity versus execution risks that could unfold, weighing future performance uncertainties. Valuation debate highlights moderate influence on investor sentiment and operational risks without fundamentally altering trajectory.
9 Mar
Innospec Inc. contends with storm fallout disrupting operations and a segment reset reshaping its business structure, leaving the stock's future direction uncertain. Storm disruptions and segment restructuring represent major operational and strategic shifts poised to significantly influence Innospec's trajectory and investor sentiment.
Innospec Inc.'s stock in FY26 gains momentum from recovery and key drivers following winter storm disruptions. Winter storm aftermath reveals major strategic drivers boosting Innospec's FY26 trajectory and investor outlook.
Innospec Inc. (IOSP) shapes FY26 strategy around drag reducing agents (DRAs) and shifts in Middle East product mix. FY26 strategy driven by DRAs and Middle East mix shifts signals major adjustments in operations and market positioning.
18 Feb
Innospec Inc. (IOSP) reported strong operating income growth in Q4 2025 earnings call highlights amid challenges. Strong operating income growth signals significant positive influence on financial performance and market trajectory.
Innospec Inc. (IOSP) Q4 earnings call highlights financial results, operational performance, strategic initiatives, and outlook for the specialty chemicals company. Q4 earnings highlights detail financial achievements and guidance shaping investor expectations and stock trajectory.
Innospec Inc. Q4 2025 earnings call summary covers quarterly financial results, operational updates, and forward guidance. Q4 earnings call summary discloses financial performance and outlook directly influencing stock valuation and investor confidence.
17 Feb
Innospec Inc. (IOSP) beat Q4 earnings estimates. Beating Q4 earnings estimates boosts investor sentiment and signals strong financial health, significantly impacting stock performance.
Innospec Inc. (IOSP) reported fourth quarter and full year 2025 financial results. Quarterly and annual earnings reports significantly impact financial performance metrics and investor sentiment toward future market performance.
Innospec Inc. (IOSP) released its Q4 earnings snapshot, detailing quarterly financial performance. Q4 earnings snapshot affects key financial metrics and short-term market sentiment.